<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534870</url>
  </required_header>
  <id_info>
    <org_study_id>M13-769</org_study_id>
    <nct_id>NCT02534870</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects</brief_title>
  <official_title>Multiple-Dose Pharmacokinetics, Safety and Tolerability of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics and safety of multiple oral doses&#xD;
      of ABT-450/ritonavir/ABT-267 and ABT-333 when co-administered under non-fasting conditions in&#xD;
      healthy Chinese adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of ABT-450</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of ABT-267</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of ABT-333</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Ritonavir</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of ABT-450</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Tmax is the time it takes for a drug to achieve Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of ABT-267</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Tmax is the time it takes for a drug to achieve Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of ABT-333</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Tmax is the time it takes for a drug to achieve Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Ritonavir</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Tmax is the time it takes for a drug to achieve Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration (Ctrough) of ABT-450</measure>
    <time_frame>Prior to the morning dose on Study Days 7, 9, 11, 13 and 14; 24 hours after Day 14 dose</time_frame>
    <description>Ctrough is the lowest concentration of a drug in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration (Ctrough) of ABT-267</measure>
    <time_frame>Prior to the morning dose on Study Days 7, 9, 11, 13 and 14; 24 hours after Day 14 dose</time_frame>
    <description>Ctrough is the lowest concentration of a drug in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration (Ctrough) of ABT-333</measure>
    <time_frame>Prior to the morning dose on Study Days 7, 9, 11, 13 and 14; 24 hours after Day 14 dose</time_frame>
    <description>Ctrough is the lowest concentration of a drug in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration (Ctrough) of Ritonavir</measure>
    <time_frame>Prior to the morning dose on Study Days 7, 9, 11, 13 and 14; 24 hours after Day 14 dose</time_frame>
    <description>Ctrough is the lowest concentration of a drug in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-450</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of Ritonavir</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-267</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC12) Post-dose of ABT-333</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, and 12 hours after the morning dose on Study Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Daily for approximately 20 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>ABT-450/r/ABT-267 + ABT-333</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 will be administered once daily in the morning and ABT-333 will be administered in the morning and evening for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450/r/ABT-267</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-450/r/ABT-267 + ABT-333</arm_group_label>
    <other_name>Paritaprevir/Ritonavir/Ombitasvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-450/r/ABT-267 + ABT-333</arm_group_label>
    <other_name>Dasabuvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Participant must be Chinese (i.e., of Chinese ancestry).&#xD;
&#xD;
        If female, participant must be either postmenopausal for at least 2 years, surgically&#xD;
        sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing&#xD;
        at least one of the following methods of birth control with male partner(s): total&#xD;
        abstinence from sexual intercourse as the preferred life style of the subject, periodic&#xD;
        abstinence is not acceptable; vasectomized partner(s); hormonal contraceptives (oral,&#xD;
        parenteral or transdermal) for at least 3 months prior to study drug administration;&#xD;
        intrauterine device (IUD); or double-barrier method (condoms, contraceptive sponge, or&#xD;
        diaphragm with spermicidal jellies or creams)&#xD;
&#xD;
        Hormonal contraceptives, including but not limited to oral, topical, injectable or&#xD;
        implantable varieties, may not be used during the study.&#xD;
&#xD;
        If male, the participant must be surgically sterile or practicing at least 1 of the&#xD;
        following methods of contraception, and refrain from sperm donation, from initial study&#xD;
        drug administration until 90 days after the last dose of study drug: partner(s) using an&#xD;
        IUD; partner(s) using oral, injected, intravaginal, or implanted methods of hormonal&#xD;
        contraceptives; participant and/or partner(s) using double-barrier method (condoms,&#xD;
        contraceptive sponge, diaphragm with spermicidal jellies or creams, or vaginal ring); or&#xD;
        total abstinence from sexual intercourse as the preferred life style of the subject;&#xD;
        periodic abstinence is not acceptable&#xD;
&#xD;
        Body Mass Index (BMI) is ≥ 18 to &lt; 30 kg/m^2.&#xD;
&#xD;
        A condition of general good health, based upon the results of a medical history, physical&#xD;
        examination, vital signs, laboratory profile, a 12-lead electrocardiogram (ECG) and chest&#xD;
        x-ray (CXR).&#xD;
&#xD;
        Exclusion Criteria: Use of any medications (prescription and over-the-counter), vitamins&#xD;
        and/or herbal supplements within the 2-week period prior to the first dose of study drug&#xD;
        administration or within 10 half-lives of the respective medication, whichever is longer.&#xD;
&#xD;
        History of epilepsy, any clinically significant cardiovascular, respiratory (except mild&#xD;
        asthma), renal, hepatic, gastrointestinal, hematologic, neurologic, thyroid, or any&#xD;
        uncontrolled medical illness or psychiatric disease or disorder.&#xD;
&#xD;
        Clinically significant abnormal ECG: ECG with QT interval corrected for heart rate using&#xD;
        Fridericia's correction formula (QTcF) &gt; 450 msec in females and &gt; 430 msec in males, or&#xD;
        ECG with second or third degree atrioventricular block.&#xD;
&#xD;
        Previous exposure to more than a single dose of ABT-450/r/ABT-267, or ABT-333 within the&#xD;
        past 12 weeks, or previous participation in this study.&#xD;
&#xD;
        Consideration by the investigator, for any reason, that the subject is an unsuitable&#xD;
        candidate to receive ABT-450, ritonavir, ABT-267, or ABT-333.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Luo, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137655</name>
      <address>
        <city>Shanghai</city>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

